Astra/Oxford seek coronavirus vaccine approval after 'effective' trials

Astra/Oxford seek coronavirus vaccine approval after 'effective' trials

Monday, November 23, 2020

Print this page Email A Friend!

LONDON,United Kingdom(AFP) — British drugs groupAstraZenecaand the University of Oxford said on Monday they will seek regulatory approval for their coronavirus vaccine after "effective" trials, in the latest potential boost to curbing the global outbreak.

The partners announced that while the vaccine showed an average 70 per cent effectiveness, the level jumped to 90 per cent depending on dosage.

Manufacturers Pfizer/BioNTech and Moderna last week said trials of their vaccines showed effectiveness above 90 per cent in what was hailed as a breakthrough in stopping the spread of the virus.

Britain's Prime Minister Boris Johnson called the announcement "incredibly exciting".

"There are still further safety checks ahead but these are fantastic results," he said.

Despite varying outcomes,AstraZenecachief executive Pascal Soriot insisted his firm's vaccine would have an "immediate impact".

"AstraZenecawill now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval," he said.

The firm said it would look to develop up to three billion doses of the vaccine in 2021 after passing regulatory hurdles.

Pfizer/BioNTech's vaccine has to be stored at -70 degrees Celsius (-94 degrees Fahrenheit) — much colder than temperatures of a standard freezer.

That has prompted questions about distribution and storage, as well as higher costs, particularly for lower-income countries.

But theAstraZeneca/Oxford vaccine could be stored, transported and handled "at normal refrigerated conditions" of between two and eight degrees Celsius for at least six months.

The vaccine showed 90 per cent efficacy when given as a half-dose followed by a full-dose at least one month apart. The result was 62 per cent as two full doses in the same period.

"We think that by giving a smaller first dose that we're priming the immune system differently, we're setting it up better to respond," Andrew Pollard, chief investigator of the Oxford Vaccine Trial, told an online press conference.

Peter Openshaw, professor of experimental medicine at Imperial College London, said a combination of half and full doses "is great news, potentially increasing the number of people that can be vaccinated and reducing costs".

- 'Save many lives' -

More than 23,000 adults in the UK and Brazil have taken part in the Astra/Oxford trials, with the number expected to rise to up to 60,000 thanks to testing also in other countries.

Early results suggested there were 131 cases of COVID-19 among the participants but none was serious.

Pollard said the latest findings suggested the drug was "aneffective vaccine that will savemany lives".

"Excitingly, we've found that one of our dosing regimens may be around 90 per cent effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply," he added.

"Today's announcement is only possible thanks to the manyvolunteers in our trial, andthehard-working andtalented teamof researchers based around the world."

US biotech giant Pfizer and German partner BioNTech have already sought approval to roll out their coronavirus vaccine early.

The move has been seen as a welcome first step towards relief as surging infections prompt a return to shutdowns that traumatised nations and the global economy earlier this year.

G20 leaders on Sunday said they would "spare no effort" to ensure the fair distribution of coronavirus vaccines worldwide and support poor countries, whose economies have been ravaged by the crisis.

But although the club of the world's richest nations adopted a unified tone, German Chancellor Angela Merkel said she was concerned that no major vaccine agreements had yet been struck for poorer nations.

Gillies O'Bryan-Tear, from the UK Faculty of Pharmaceutical Medicine, said theAstraZeneca/Oxford vaccine had a "great advantage" over Pfizer/BioNTech and Moderna.

"It can be manufactured easily and transported at ordinary fridge (not freezer) temperatures, so can be transported and stored using the existing vaccine cold chain infrastructure.

"The group has promised to provide the vaccine not-for-profit to developing nations," he said.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon